Maat Pharma SA - Asset Resilience Ratio

Latest as of June 2025: 0.06%

Maat Pharma SA (MAAT) has an Asset Resilience Ratio of 0.06% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Maat Pharma SA to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€31.00K

≈ $36.24K USD Cash + Short-term Investments

Total Assets

€48.88 Million

≈ $57.14 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2024)

This chart shows how Maat Pharma SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MAAT asset base.

Liquid Assets Composition Over Time

This chart breaks down Maat Pharma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read MAAT total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€31.00K	0.06%
Total Liquid Assets	€31.00K	0.06%

Asset Resilience Insights

Limited Liquidity: Maat Pharma SA maintains only 0.06% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Maat Pharma SA Industry Peers by Asset Resilience Ratio

Compare Maat Pharma SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Genscript Biotech Corporation F:G51	Biotechnology	13.79%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
89bio Inc NASDAQ:ETNB	Biotechnology	71.60%
Pacific Shuanglin Bio pharmacy Co Ltd SHE:000403	Biotechnology	2.66%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%

Annual Asset Resilience Ratio for Maat Pharma SA (2022–2024)

The table below shows the annual Asset Resilience Ratio data for Maat Pharma SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	22.75%	€8.76 Million ≈ $10.24 Million	€38.50 Million ≈ $45.01 Million	-22.54pp
2023-12-31	45.29%	€19.44 Million ≈ $22.73 Million	€42.93 Million ≈ $50.19 Million	+3.69pp
2022-12-31	41.60%	€18.61 Million ≈ $21.75 Million	€44.73 Million ≈ $52.29 Million	--

pp = percentage points

About Maat Pharma SA

PA:MAAT France Biotechnology

Market Cap

$35.73 Million

€30.56 Million EUR

Market Cap Rank

#23277 Global

#363 in France

Share Price

€1.63

Change (1 day)

-18.50%

52-Week Range

€1.08 - €7.78

All Time High

€13.95